Table 3: Effects of WEFM, WEGT, and four marker compounds on reducing activity and liposome protection.

Samples( 𝜇 g/m)Reducing activity
Liposome protection
( 𝜇 g VitC/mL)(%)

WEFM
50 1 0 . 2 ± 0 . 2 4 6 . 7 ± 2 . 1
100 2 0 . 1 ± 0 . 3 6 7 . 5 ± 0 . 4
WEGM50 4 . 5 ± 0 . 1 2 4 . 5 ± 1 . 5
100 7 . 7 ± 0 . 2 4 3 . 3 ± 1 . 0
Daidzin50 2 . 9 ± 0 . 1 4 0 . 0 ± 0 . 8
100 4 . 9 ± 0 . 1 6 3 . 6 ± 0 . 6
Daidzein50 5 . 3 ± 0 . 2 4 5 . 2 ± 1 . 4
100 6 . 3 . ± 0 . 2 5 9 . 1 ± 2 . 1
Genistin50 9 . 2 ± 0 . 4 6 2 . 4 ± 1 . 8
100 1 3 . 4 ± 0 . 6 7 4 . 0 ± 1 . 1
Genistein50 9 . 8 ± 0 . 5 6 4 . 2 ± 2 . 5
100 1 3 . 7 ± 0 . 3 7 8 . 6 ± 2 . 8

The data were displayed with mean ± S.D. of three experiments individually and analyzed by ANOVA ( 𝑃 < 0 . 0 5 ).